ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,201.20
0.52%
S&P ASX All Technology
3,814.30
0.23%
Brent Oil
75.595
2.36%
US Dollar vs AUD
1.60927
-0.33%
Bitcoin
96,652.33
2.40%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Caribou Biosciences Inc (CRBU) Share Price

Caribou Biosciences Inc

Caribou Biosciences Inc (CRBU)

Amd Commo Exagr
1.59
-0.02
(-1.24%)
Closed 01 January 8:00AM
Delayed by 15 minutes
1.59
0.00
( 0.00% )
Pre Market: 9:09PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.59
Bid
1.59
Offer
1.68
Volume
1,000
0.00 Day's Range 0.00
1.50 52 Week Range 8.33
Market Cap
143.979M
Previous Close
1.59
Open
-
Last Trade
495
@
1.59
(formt)
Last Trade Time
20:53:18
Financial Volume
-
VWAP
-
Average Volume (3m)
1,450,965
Shares Outstanding
90,552,687
Dividend Yield
-
PE Ratio
-1.41
Earnings Per Share (EPS)
-1.13
Revenue
34.48M
Net Profit
-102.07M

About Caribou Biosciences Inc

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.cariboubio.com
Headquarters
Dover, Delaware, USA
Founded
-
Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was US$1.59. Over the last year, Caribou Biosciences shares have traded in a share price range of US$ 1.50 to US$ 8.33.

Caribou Biosciences currently has 90,552,687 shares in issue. The market capitalisation of Caribou Biosciences is US$143.98 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.41.

Ask ADVFN Intelligence (AI)

CRBU Latest News

More News

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

07 December 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

23 November 2024
Edgar (US Regulatory)

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...

21 November 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

15 November 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 November 2024
Edgar (US Regulatory)

Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update

-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after...

07 November 2024
GlobeNewswire Inc.

Form 3 - Initial statement of beneficial ownership of securities

05 October 2024
Edgar (US Regulatory)

Form 8-K/A - Current report: [Amend]

28 September 2024
Edgar (US Regulatory)

Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an...

25 September 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1-5.917159763311.691.751.5415678501.6373235CS
4-0.46-22.43902439022.052.261.5414035811.84995295CS
12-0.26-14.05405405411.852.99951.5414509652.1006231CS
26-0.01-0.6251.62.99951.513588072.10351231CS
52-4.12-72.15411558675.718.331.516735753.30692529CS
156-13.55-89.498018494115.1415.851.513134265.26990282CS
260-16.06-90.991501416417.6532.6451.512281456.44770972CS

CRBU - Frequently Asked Questions (FAQ)

What is the current Caribou Biosciences share price?
The current share price of Caribou Biosciences is US$ 1.59
How many Caribou Biosciences shares are in issue?
Caribou Biosciences has 90,552,687 shares in issue
What is the market cap of Caribou Biosciences?
The market capitalisation of Caribou Biosciences is USD 143.98M
What is the 1 year trading range for Caribou Biosciences share price?
Caribou Biosciences has traded in the range of US$ 1.50 to US$ 8.33 during the past year
What is the PE ratio of Caribou Biosciences?
The price to earnings ratio of Caribou Biosciences is -1.41
What is the cash to sales ratio of Caribou Biosciences?
The cash to sales ratio of Caribou Biosciences is 4.18
What is the reporting currency for Caribou Biosciences?
Caribou Biosciences reports financial results in USD
What is the latest annual turnover for Caribou Biosciences?
The latest annual turnover of Caribou Biosciences is USD 34.48M
What is the latest annual profit for Caribou Biosciences?
The latest annual profit of Caribou Biosciences is USD -102.07M
What is the registered address of Caribou Biosciences?
The registered address for Caribou Biosciences is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
What is the Caribou Biosciences website address?
The website address for Caribou Biosciences is www.cariboubio.com
Which industry sector does Caribou Biosciences operate in?
Caribou Biosciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RAINRain Enhancement Technologies Holdco Inc
 11.50
(850.41%)
150
ALCEAlternus Clean Energy Inc
US$ 1.96
(149.43%)
16.62M
AEIAlset Inc
US$ 2.43
(138.24%)
12.16M
CMCTCreative Media and Community Trust Corporation
US$ 0.4218
(87.47%)
29.94M
DMRCDigimarc Corporation
US$ 58.40
(55.94%)
1.28k
BDMDBaird Medical Investment Holdings Ltd
US$ 4.81
(-36.71%)
250.35k
SIDUSidus Space Inc
US$ 3.49
(-28.78%)
936.68k
AIPArteris Inc
US$ 8.01
(-21.39%)
49
BFINBankFinancial Corporation
US$ 10.01
(-21.15%)
9
LNSRLENSAR Inc
US$ 7.15
(-20.02%)
1
CMCTCreative Media and Community Trust Corporation
US$ 0.4113
(82.80%)
30.08M
SVMHSRIVARU Holding Ltd
US$ 0.04
(-4.99%)
26.24M
CGBSCrown LNG Holdings Ltd
US$ 0.607
(51.71%)
21.56M
ALCEAlternus Clean Energy Inc
US$ 1.98
(151.97%)
16.62M
AEIAlset Inc
US$ 2.43
(138.24%)
12.16M

CRBU Discussion

View Posts
Monksdream Monksdream 2 weeks ago
CRBU under $2
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
CRBU READY TO BEAST
👍️0
TrendTrade2016 TrendTrade2016 2 months ago
CRBU...NEW SCAN JUST GAVE ME THIS BIO
👍️0
Monksdream Monksdream 2 months ago
CRBU under $3
👍️0
Monksdream Monksdream 3 months ago
CRBU under $2
👍️0
Monksdream Monksdream 4 months ago
CRBU under $3
👍️0
Monksdream Monksdream 5 months ago
CRBU under $3
👍️0
jondoeuk jondoeuk 5 months ago
Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

This should extend their cash runway by at least six months, into the second half of 2026.
👍️0
Monksdream Monksdream 5 months ago
CRBU under $3
👍️0
Monksdream Monksdream 6 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 6 months ago
CRBU new 52 week low
👍️0
NY1972 NY1972 7 months ago
Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
👍️0
Diego Rivas Diego Rivas 7 months ago
Any good news in here comming?
👍️0
jondoeuk jondoeuk 7 months ago
Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
👍️0
jondoeuk jondoeuk 7 months ago
The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

* CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
👍️0
Monksdream Monksdream 7 months ago
CRBU new 52 week low
👍️0
stocksrising stocksrising 7 months ago
Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
👍️0
jondoeuk jondoeuk 7 months ago
It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
👍️ 1
Monksdream Monksdream 7 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 8 months ago
CRBU new 52 week low
👍️0
Monksdream Monksdream 8 months ago
CRBU under $5
👍️0
stocksrising stocksrising 10 months ago
It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
👍️0
Monksdream Monksdream 1 year ago
CRBU new 52 week low
👍️0
jondoeuk jondoeuk 1 year ago
Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
👍️0
trueblue trueblue 1 year ago
.
👍️0
trueblue trueblue 1 year ago
$23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
👍️0
NY1972 NY1972 1 year ago
Didn't they buy TRIL? Just gambling with billions from US government.
👍️0
jondoeuk jondoeuk 1 year ago
PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
👍️0
trueblue trueblue 1 year ago
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
👍️0
Monksdream Monksdream 1 year ago
CRBU now No 9 on the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
trueblue trueblue 1 year ago
Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
👍️0
Stockexpertpro Stockexpertpro 1 year ago
CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
👍️0
TheFinalCD TheFinalCD 1 year ago
CRBU= JUST WOW

https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
👍️0
Monksdream Monksdream 1 year ago
CRBU No 1 on the early Barchart Top 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

NASDAQ
CRBU
Caribou Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads